Skip to main content
Glama

Here

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/openWorld/idempotent annotations, the description discloses important behavioral nuances: graceful degradation when GLEIF or OpenFIGI is unavailable, cascading internal lookups, conditional parent/ownership data, and the fact that ISINs resolve to the issuing legal entity. This substantially enriches the agent's understanding of what the call will and will not produce.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with user-intent examples and a clear 'use first' directive, and every section earns its place given the tool's complexity. However, the long parenthetical-heavy sentences and nested clarifications make it denser and harder to parse than ideal, slightly reducing conciseness.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite lacking an output schema, the description fully explains what types of results are returned for each entity type (CIK, ticker, company name, LEI, FIGI, RxCUI, ingredient, brand, citation), including edge cases like non-US issuers and instruments without tickers. No critical operational aspect is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though schema coverage is 100%, the description adds critical parameter semantics beyond the schema: accepted input forms (ticker, CIK, ISIN, or name), what value should contain for bonds versus full noun phrases, and the distinction between brand and generic drug names. This is exactly the kind of practical guidance that prevents incorrect invocation.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool's purpose with specific verbs: it resolves user-spoken names and identifiers to canonical/official identifiers required by other tools. The extensive query examples and supported types (company, drug) make the resource and scope immediately obvious, and it distinguishes itself as the identifier-resolution step rather than a profiling or research tool.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit usage rule: 'Use FIRST whenever you have a name but need an ID.' It also clarifies what kinds of instruments resolve here (including non-equity instruments) and notes that it replaces 2-3 manual lookups. However, it does not explicitly name alternative tools or state when not to use it, so the guidance is strong but not fully exclusionary.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Here toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation2/5

Several tools overlap heavily: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, and suggest_questions all route questions to the same underlying data catalog, making it hard to pick the right one. The Polymarket-related tools (bet_research, polymarket_edges, polymarket_arbitrage, polymarket_fill_risk, polymarket_edge_tracker, polymarket_kalshi_spread) also have overlapping discovery and analysis purposes.

Naming Consistency3/5

Many tools use descriptive snake_case, and the ask_pipeworx family shares a clear prefix, but the set mixes generic memory verbs (remember, recall, forget), brand-prefixed tools (here_*, pipeworx_*), and standalone names like bet_research and scan_dependency. There is no consistent verb_noun pattern across the whole server.

Tool Count2/5

35 tools is heavy for a single MCP server, and a large portion are meta-tools layered over the same 5,752-tool catalog (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, discover_tools, suggest_questions). The broad intentional scope explains the count, but the tool surface feels bloated and harder to navigate than it needs to be.

Completeness4/5

The domain is unusually broad—data querying, entity resolution, comparison, monitoring, memory, geolocation, prediction markets, dependency scanning—and the set covers most workflows end to end. Minor gaps exist, like no direct pipeworx:// citation fetcher and no update/list/delete pattern for entity profiles, but the core user journeys are well supported.

Resources